COMPANY

Prokaryotics

HQ: Union, NJ source · prokaryotics.com ↗ · Mid-Atlantic

Keywords: infectious disease

Location: Union, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

21NIH grants

Funding and NIH signals

NIH award NIH awarded $977K (SBIR Phase II 5R44AI165008-03, continuation, notice Jun 3, 2026); 3 NIH awards totaling $1.86M in the last 12 months. NIH RePORTER 5R44AI165008-03 (Jun 3, 2026)
Evidence (3 events)
- Jun 3, 2026 · NIH RePORTER 5R44AI165008-03
  Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R44AI165008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 977454; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics; Organization type: Domestic For-Profits
- Feb 17, 2026 · NIH RePORTER 5R21AI185171-02
  Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R21AI185171-02; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-02-17; FY total cost (award amount): 204000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4; Organization type: Domestic For-Profits
- Feb 2, 2026 · NIH RePORTER 5R01AI165740-04
  Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R01AI165740-04; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-02; FY total cost (award amount): 679600; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 3, 2026 Grant Government grant — SBIR: $977,454 (annual award, as published), announced Jun 3, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 17, 2026 Grant Government grant — NIH R21: $204,000 (annual award, as published), announced Feb 17, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 2, 2026 Grant Government grant — NIH R01: $679,600 (annual award, as published), announced Feb 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 19, 2025 Grant Government grant — SBIR: $299,697 (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Grant Government grant — SBIR: $996,450 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jan 31, 2025 Grant Government grant — NIH R21: $170,000 (annual award, as published), announced Jan 31, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Oct 29, 2024 Grant Government grant — NIH R01: $679,683 (annual award, as published), announced Oct 29, 2024. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Jun 3, 2026 Government grant — SBIR: $977,454 (annual award, as published), announced Jun 3, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 17, 2026 Government grant — NIH R21: $204,000 (annual award, as published), announced Feb 17, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 2, 2026 Government grant — NIH R01: $679,600 (annual award, as published), announced Feb 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 19, 2025 Government grant — SBIR: $299,697 (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Government grant — SBIR: $996,450 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jan 31, 2025 Government grant — NIH R21: $170,000 (annual award, as published), announced Jan 31, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Oct 29, 2024 Government grant — NIH R01: $679,683 (annual award, as published), announced Oct 29, 2024. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 21

Annual award amounts. Total $12.7M.

Jul 30, 2024 NIH award 5R42AI179344-02 FY2024: $295,592 awarded for that fiscal year; activity R42 (STTR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a novel broad spectrum antifungal th source ↗
Jun 5, 2024 NIH award 5R44AI136213-06 FY2024: $974,575 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a PO-administered beta-lactam-taroci source ↗
Oct 25, 2023 NIH award 5R01AI165740-02 FY2024: $679,343 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a mechanistically novel Gram-ne source ↗
Aug 15, 2023 NIH award 1R42AI179344-01 FY2023: $299,326 awarded for that fiscal year; activity R42 (STTR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a novel broad spectrum antifungal th source ↗
Jun 21, 2023 NIH award 5R44AI136213-05 FY2023: $991,117 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a PO-administered beta-lactam-taroci source ↗
Jun 15, 2023 NIH award 5R21AI171153-02 FY2023: $204,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI SUTTERLIN, HOLLY ANN; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of LspA Inhibitors to Treat source ↗
Nov 4, 2022 NIH award 1R01AI165740-01A1 FY2023: $679,343 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a mechanistically novel Gram- source ↗
Aug 26, 2022 NIH award 1R44AI165008-01A1 FY2022: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a mechanistically novel synergisti source ↗
Jul 20, 2022 NIH award 5R44AI145409-03 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of WecA-targeting immune potentiators source ↗
Jul 8, 2022 NIH award 2R44AI136213-04 FY2022: $999,396 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a PO-administered beta-lactam-taroci source ↗
Jun 28, 2022 NIH award 1R21AI171153-01 FY2022: $170,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI SUTTERLIN, HOLLY ANN; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of LspA Inhibitors to Treat source ↗
Aug 16, 2021 NIH award 4R44AI145409-02 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of WecA-targeting immune potentiators source ↗
Jul 30, 2021 NIH award 5R21AI146541-02 FY2021: $140,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Characterization of MsbA inhibitors as potenti source ↗
Aug 19, 2020 NIH award 1R21AI146541-01A1 FY2020: $245,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Characterization of MsbA inhibitors as poten source ↗
Jul 8, 2020 NIH award 5R44AI138688-03 FY2020: $842,442 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a novel agent to treat antimicrobial source ↗
Nov 26, 2019 NIH award 5R44AI136213-03 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Restoring Beta-lactam efficacy against methicilli source ↗
Jul 26, 2019 NIH award 1R44AI145409-01 FY2019: $295,541 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of WecA-targeting immune potentiators t source ↗
Jun 28, 2019 NIH award 4R44AI138688-02 FY2019: $952,958 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a novel agent to treat antimicrobial source ↗
Dec 24, 2018 NIH award 4R44AI136213-02 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Restoring Beta-lactam efficacy against methicilli source ↗
Jun 14, 2018 NIH award 1R44AI138688-01A1 FY2018: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Development of a novel agent to treat antimicrobi source ↗
Feb 2, 2018 NIH award 1R44AI136213-01 FY2018: $299,999 awarded for that fiscal year; activity R44 (SBIR); PI ROEMER, TERRY; recipient as written: PROKARYOTICS, INC., UNION, NJ. Restoring Beta-lactam efficacy against methicillin- source ↗